ASXL1 and chronic myelomonocytic leukemia: Table 1 shows the frequencies of gene mutations in 3 different CMML cohorts in which comprehensive molecular analyses has been reported (9, 11, 32). Considering all molecular data reported mutations in TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%) and RAS pathway (~30%) are most common (15) but no molecular aberration is specific of this entity, as they can be detected with different frequencies in other myeloid neoplasms (33).